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Abstract 
Introduction: Perinatal mortality rate and the rate of preterm birth (10-12%) in pregnant women with hypertensive 
disorders far outweigh the corresponding values in women with physiological pregnancy. Despite such close attention 
worldwide to this problem, today the number of this complication has no tendency to decrease. 
Objective of the study: To study the protective effect of arginase II selective inhibitors KUD–974, KUD–975, KUD–259 
on functional parameters in rats with ADMA–like preeclampsia. 
Methods: The study was conducted in 140 female Wistar rats weighing 250-300 g. 
Results: The analysis of the obtained in this experimental study results showed that a decrease in the activity of arginase 
leads to an increase in the production of nitric oxide, which has a beneficial effect on vascular function. 
Conclusion: Arginase II inhibitors are currently a promising group of drugs for the treatment of hypertensive conditions in 
pregnant women. 
Key words: Preeclampsia, Arginase Inhibitors, Endothelial Dysfunction. 
Introduction 
Over the past decade, preeclampsia, which is a 
special case of hypertensive disorders during 
pregnancy, has been the object of increased attention, 
as this complication causes every 3rd case of obstetric 
morbidity and annually takes up to 50,000 lives of 
young women around the world and is the most 
common cause in the structure of maternal mortality 
[1-3,]. Perinatal mortality rates and the rate of preterm 
birth (10-12%) in pregnant women with hypertensive 
disorders far outweigh the corresponding values in the 
women with normal pregnancy. The incidence of 
preeclampsia during pregnancy ranges from 2 to 8% 
[4-6]. Despite such close attention to this problem all 
over the world, today the number of cases of this 
complication does not tend to decrease [7, 8].  
In recent years, the number of studies indicating 
that the main role in the development of preeclampsia 
plays a disorders of the endothelial function, which 
lead to development of generalized spasm, increase in 
blood pressure and, as a consequence, ischemic 
disorders in organs [9, 10, 24]. Endothelium is a 
powerful endocrine organ involved in the regulation 
of vascular tone and maintenance of their normal 
structure, control of blood rheology and processes of 
local inflammation. Normally, anticoagulant and 
antithrombotic activity of the endothelium prevail 
over procoagulant activity, but in the conditions of 
damage this balance is shifted towards 
procoagulation.  
One of the factors in the development of 
endothelial dysfunction is a deficiency of nitric oxide 
(NO), which is the main vasodilating factor produced 
by the endothelium. In the physiological pregnancy, 
one of the adaptive mechanisms of the cardiovascular 
system of a woman is to increase the endogenous 
production of NO and increase the sensitivity of 
smooth muscle vascular cells to it.  
No synthesis is carried out under the action of the 
enzyme endothelial NO-synthase (eNOS) from the 
amino acid L-arginine. Arginase inhibitors are 
substances of natural origin, the mechanism of action 
of which is to block the enzyme arginase, and, 
consequently, in prevention of the metabolism of L-
arginine into ornithine and urea [11, 12, 22, 23]. As a 
result, a greater amount of L-arginine is metabolized 
to nitric oxide under the action of NO-synthase [13-
15, 21]. Reduced arginase activity leads to increased 
production of nitric oxide, which has a positive effect 
on the endothelial function. Thus, the administration 
of arginase inhibitors to increase the synthesis of NO 
is one of the methodological approaches to prevent 
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the development of endothelial dysfunction [16-18, 
20, 25]. 
Objective of the Study 
To study the protective effect of arginase II 
selective inhibitors KUD–974, KUD–975, KUD–259 
on functional parameters in rats with ADMA–like 
preeclampsia. 
Methods 
The study was performed on 140 female Wistar 
rats weighing 250-300 g. ADMA-like preeclampsia in 
the studied animals was simulated by the 
administration of a non-selective NOS inhibitor L-
Nitro-Arginine Methyl Ester (L-NAME) (25 
mg/kg/day) intraperitoneally from the 14th to the 20th 
day of the pregnancy. Arginase II selective inhibitors 
KUD 259, KUD 974, KUD 975 were administered to 
the experimental animals at the dose of 1 mg/kg/day 
per os from the 14th to the 20th day of the pregnancy. 
Methyldopa, which was administered at the dose of 
0.043 g/kg twice a day per os from the 14th to the 
20th day of the pregnancy, and L-Norvaline 10 
mg/kg/day per os from the 14th to the 20th day of 
pregnancy, were selected as drugs for animal control 
groups. 
Results 
The administration of the arginase II selective 
inhibitors in the animals with ADMA-like 
preeclampsia leaded to a statistically significant (p 
<0.05) decrease in blood pressure levels in 
comparison with the group of untreated animals (Fig. 
1). 
 
Figure -1: The effect of the arginase II selective 
inhibitors on the blood pressure of rats with ADMA-
like preeclampsia 
Note: *- p <0.05 in comparison with the group of 
intact animals; y - p <0.05 in comparison with L-
NAME group; *y - p <0.05 the comparison of the 
intact animals group with L-NAME group. 
The evaluation of the endothelial function revealed 
a statistically significant (p <0.05) improvement in the 
endothelial dysfunction coefficient in animals with 
ADMA-like preeclampsia which were administered 
by the arginase II selective inhibitors in comparison 
with the group of untreated animals (Fig. 2). 
 
Figure-2: The effect of the arginase II selective 
inhibitors on the endothelial dysfunction coefficient 
in rats with ADMA-like preeclampsia 
Note: *- p <0.05 in comparison with the group of 
intact animals; y - p <0.05 in comparison with L-
NAME group; *y - p <0.05 the comparison of the 
intact animals group with L-NAME group. 
The analysis of the concentration level of nitric 
oxide terminal metabolites in the plasma of rats with 
ADMA – like preeclampsia showed a statistically 
significant (p <0.05) increase in the groups of animals 
with ADMA-like preeclampsia, which were 
administered by the arginase II selective inhibitors in 
comparison with the group of untreated animals (Fig. 
3). 
 
Figure -3: The effect of the arginase II selective 
inhibitors on the concentration of the nitric oxide 
terminal metabolites in the plasma of rats with 
ADMA – like preeclampsia. 
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Note: *- p <0.05 in comparison with the group of 
intact animals; y - p <0.05 in comparison with L-
NAME group; *y - p <0.05 the comparison of the 
intact animals group with L-NAME group. 
The evaluation of a placental microcirculation in 
the in experimental animals revealed a statistically 
significant (p <0.05) increase of the microcirculation 
values in comparison with the group of untreated 
animals (Fig. 4). 
 
Figure-4: The effect of the arginase II selective 
inhibitors on the placental microcirculation in rats 
with ADMA–like preeclampsia 
Note: *- p <0.05 in comparison with the group of 
intact animals; y - p <0.05 in comparison with L-
NAME group; *y - p <0.05 the comparison of the 
intact animals group with L-NAME group. 
Conclusion 
The performed study revealed a pronounced 
protective effect of the arginase II selective inhibitors 
KUD–974, KUD–975, KUD–259 on the functional 
parameters in rats with ADMA–like pre-eclampsia.  
In this study, endothelial dysfunction was chosen 
as a target for the search for new drugs for the 
prevention and treatment of preeclampsia, as a 
dysfunction of small arterial vessels leads to disorders 
of the blood pressure regulation and microcirculation 
in tissues, which lead to a dysfunction of organs and 
systems, and in some cases to multiorgan failure.  
The evaluation the results obtained in this 
experimental study, found that a decrease in the 
arginase activity leads to an increase in the production 
of nitric oxide, which has a beneficial effect on 
vascular function. Thus, the application of arginase 
inhibitors to increase the NO synthesis is one of the 
methodological approaches to prevent the endothelial 
dysfunction.  
Treatment used by modern obstetrics and 
gynecology doctors in daily practice, focused on 
reducing the dominant syndromes underestimation of 
the pathogenetic components. Modern knowledge of 
the preeclampsia pathogenesis and the accumulated 
experimental data justify the foreseeable prospects for 
the development of drugs for the preeclampsia 
treatment and prevention and reveal new opportunities 
for further research. Therefore, today it is important to 
search for new pharmacological agents that can stop 
this complication of pregnancy, affecting the 
development and course of preeclampsia. Thus, it can 
be assumed that arginase inhibitors are currently a 
promising group of drugs for the treatment of 
hypertensive conditions in pregnant women. Arginase 
II inhibitors are of particular interest, given their 
selectivity. 
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